Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MaGMa

Financiado

Cerrado

Applying Metabolomics to Unveil follow up treatment biomarkers and Identify Nove...

Applying Metabolomics to Unveil follow up treatment biomarkers and Identify Novel Therapeutic Targets in Glioblastoma Glioblastoma multiforme (GBM) is the most common and devastating form of malignant brain tumour, containing self-renewing, tumorigenic cancer stem cells (CSCs) that contribute to tumour initiation and therapeutic resistance. The s... ver más

03/04/2020

CEU

158K€

Presupuesto del proyecto: 158K€

Líder del proyecto

FUNDACION UNIVERSITARIA SAN PABLO CEU No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 20

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-04-03

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CEU

158.12K€ | Lider

Proyectos interesantes

SAF2016-80639-P

Medical Technol...

Data Science

218K€ Cerrado

SENSITIVITYMARKERS

Medical Technol...

Data Science

71K€ Cerrado

SAF2015-64927-C2-2-R

Medical Technol...

Data Science

109K€ Cerrado

TECNEC

Medical Technol...

Data Science

3M€ Cerrado

BIO2017-85364-R

Medical Technol...

Data Science

242K€ Cerrado

EUIN2015-62801

Medical Technol...

Data Science

16K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 25 meses Fecha Inicio: 2018-02-23
Fecha Fin: 2020-04-03

Líder del proyecto

FUNDACION UNIVERSITARIA SAN PABLO CEU No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 20

Presupuesto del proyecto 158K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Glioblastoma multiforme (GBM) is the most common and devastating form of malignant brain tumour, containing self-renewing, tumorigenic cancer stem cells (CSCs) that contribute to tumour initiation and therapeutic resistance. The survival of such patients has not improved so much in the last 60 years, and we are still far to get any cure. Therefore, new methods for prognosis and diagnosis are needed, and it could come from better understanding of glioma biology. The link between cancer and altered metabolism is not new. Many observations were made during the early period of cancer biology research, identifying metabolic changes as a common feature of cancerous tissues to adapt to the necessities of the tumour. GBM comprises several phenotypic subtypes, each with distinguishing hallmark mutations, copy number alterations, epigenetic alterations, and clinical features, generating a different treatment efficacy. We believe that GBM subtypes will produce different patterns in the metabolite fingerprint and moreover the use of treatments will change them. In the present project we will use a metabolomic approach on a model of human CSCs isolated from fresh surgical tissue, to characterize two of the most extreme phenotypes; proneural and mesenchymal. We will map the tumour metabolite profile and the translation of this knowledge may lead to more personalized therapies. Besides that, we are interested in studying the metabolite profile of the extracellular vesicles (EV) released by those subtypes. This research effort is not only necessary to map the metabolome of EVs from different origins, but also to elucidate whether or not the metabolites are directly packaged into specific EVs, their possible function in surrounding cells, as the possibility of finding different metabolite profiles characteristic of tumour subtypes and moreover with a differential response to drugs that could be use as biomarkers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores